

# **Antibiotic efflux: from discovery to epidemiological, clinical, and veterinary impact**

**Françoise Van Bambeke & Paul M. Tulkens**

Pharmacologie cellulaire et moléculaire  
Louvain Drug Research Institute  
Université catholique de Louvain, Brussels, Belgium



[<www.facm.ucl.ac.be>](http://www.facm.ucl.ac.be)

# Discovery and significance ....




# Chemotherapeutic agents exert toxic effects on specific target cells

antibiotics




antifungals




anticancer agents

# Chemotherapeutic agents exert toxic effects on specific target cells




**How can these drugs  
reach their target inside the cells ?**

# Reaching an intracellular target ...





**physico-chemical properties are inadequate  
for reaching an intracellular target !**

# Reaching an intracellular target ...



# Intracellular chemotherapeutic agents




**But a diffusible compound  
may have  
potentially harmful effects !**




# Why efflux transporters ?

## Extrusion by efflux pumps



# Why efflux transporters ?


## Extrusion by efflux pumps



**general mean of protection  
against cell invasion by diffusible molecules**

# Most antibiotics are amphiphilic !


## cationic amphiphiles




Van Bambeke et al. (2000) Biochem. Pharmacol. 60:457-70

# Most antibiotics are amphiphilic !

## anionic amphiphiles



# Antibiotic efflux transporters are ubiquitous




Mesaros et al. (2005) Louvain médical. 124:308-20

# Antibiotics as substrates of efflux pumps

Antibiotic class	bacteria		fungi	superior eucaryotes
	Gram (+)	Gram (-)		
β-lactams	●		●	●
fusidic acid			●	
macrolides	●		●	●
streptogramins	●			●
tetracyclines	●		●	●
aminoglycosides			●	●
chloramphenicol	●		●	
rifamycins				●
sulfamides			●	
trimethoprim		●		
fluoroquinolones	●		●	●


Van Bambeke et al. (2000) Biochem. Pharmacol. 60:457-70

# Antibiotic efflux and resistance: time line ...



# Efflux as a mechanism of export in antibiotic producers

## spectrum



specific for the produced antibiotic

ABC

OleB or C of *S. antibioticus*  
→ [oleandomycin](#)  
SmB of *S. ambofaciens*  
→ [macrolides](#)  
Tlrc of *S. fradiae*  
→ [tylosin](#)


MFS

Ptr of *S. pristinaespiralis*  
→ [pristinamycin](#)  
LmrA of *S. lincolnensis*  
→ [lincomycin](#)  
RifP of *A. mediterranei*  
→ [rifampicin](#)

# Efflux as a mechanism of resistance in Gram-positive bacteria

## spectrum

narrow



specific for one (or a few) families of drugs


ABC

PatA/PatB of *S. pneumoniae*  
→ FQ, chl  
MsrA of *S. epidermidis*  
→ erythromycin

MFS

NorA of *S. aureus*  
→ FQ, Tet, chl  
MefE of *S. pneumoniae*  
→ ML  
PmrA of *S. pneumoniae*  
→ FQ  
MefA of *S. pyogenes*  
→ ML

# FQ efflux pumps in *S. pneumoniae*



Primary transporters  
« **ATP-Binding Cassette** »

**PatA/PatB**

*Marrer et al, AAC 2006; 50:685-93*



Secondary transporters  
(Proton motive force)

**PmrA**

*Gill et al, AAC 1999; 43:187-9*




*Terry et al., Nature Reviews Microbiology 2005; 3: 566-572*

# Efflux as a mechanism of resistance in Gram-negative bacteria

## spectrum

narrow



specific for one (or a few) families of drugs

MFS

TetA of *E. coli*

→ Tet

MsrA of *S. epidermidis*

→ erythromycin

broad spectrum, conferring cross-resistance

RND

MexAB-OprM of *P. aeruginosa*

→ β-lac, FQ, Tet, ML, chl, rif, sulf

AcrAB-TolC of *E. coli*

→ β-lac, FQ, Tet, ML, chl, rif, sulf

# Efflux and resistance in *P. aeruginosa*

Constitutive  
basal expression  
overexpressed  
upon induction

No basal  
expression;  
expression  
upon induction

MexB      MexY


MexD      MexF

MexA      MexX

MexC      MexE

OprM      OprM

OprJ      OprN



CM: cytoplasmic membrane  
(membrane cytoplasmique)

CMP: cytoplasmic membrane protein  
(protéine de la membrane cytoplasmique)


EM: external membrane  
(membrane externe)

MFP: membrane fusion protein  
(protéine de fusion [entre membranes])

P: porin  
(porine)


OMP: outer membrane protein  
(protéine de membrane externe)

# Role of antibiotic efflux in epidemiology and resistance ....



# Does efflux mean « resistance » vs. epidemiological breakpoints ?


MICs vs breakpoints for 183 *S. pneumoniae* isolated from CAP



- Efflux (+) strains considered as susceptible
- FQ with high intrinsic activity can be substrates for efflux !

# Does efflux mean « resistance » vs. epidemiological breakpoints ?

MICs vs EUCAST breakpoints for 109 *P. aeruginosa* without or with efflux mechanisms, isolated from ICU patients (VAP)



# Efflux and intrinsic resistance


Is *Pseudomonas* « intrinsically » resistant to temocillin ?

Strain	Description	Efflux characteristics					MIC (mg/L)	
		Gene expression level					temocillin (+ PAβN <sup>c</sup> )	ticarcillin (+ PAβN <sup>c</sup> )
		<i>mexA</i> <sup>a</sup>	<i>mexX</i> <sup>a</sup>	<i>oprM</i> <sup>a</sup>	<i>mexC</i> <sup>b</sup>	<i>mexE</i> <sup>b</sup>		
<b>Reference strain</b>								
PAO1		1	1	1	-	-	256-512 (64)	32 (16)
<b>Engineered strains</b>								
CB 536	PAO1 <i>ΔmexCD-oprJ</i>	1.09	1.65	ND	-	+	128 (16)	8 (1)
CB603	PAO1 <i>ΔmexEF-oprN</i>	1.21	1.02	0.51	-	-	128 (32)	16 (16)
CB602	PAO1 <i>mexXY::FRT</i>	1.10	0.06	0.55	-	+	64 (16)	16 (16)
PAO1 mexAB	PAO1 <i>mexAB::FRT</i>	0 <sup>m</sup>	1.08	ND	-	+	4 (2)	2 (2)

MexAB-OprM mutants are highly susceptible!

# Efflux and intrinsic resistance

Is *Pseudomonas* « intrinsically » resistant to macrolides ?



Major role  
of constitutively-expressed  
transporters!

# Role of efflux pumps in the clinics ...




# FQ resistance by efflux in *S. pneumoniae* is mediated by PatA/PatB

FQ strains	CIP		MXF	
	-Res	+Res	-R	+R
49619	1	0.5	0.125	0.125
$\Delta patA$	0.5	0.5	0.125	0.125
$\Delta patB$	0.5	0.5	0.125	0.125
$\Delta pmrA$	1	0.5	0.125	0.125
SP335	32	2	0.5	0.25
$\Delta patA$	1	0.5	0.125	0.125
$\Delta patB$	1	0.5	0.125	0.125
$\Delta pmrA$	8	0.5	0.25	0.125

CIP affected but not MXF !

# FQ induce efflux, whether substrates or not




Both  
CIP and MXF  
are inducers !

# Selection of resistance in *S. pneumoniae* by subMIC concentrations of FQ

ciprofloxacin

■ CIP  
□ CIP + reserpine



Ciprofloxacin selects  
for resistance by efflux


# Selection of resistance in *S. pneumoniae* by subMIC concentrations of FQ

moxifloxacin

GyrA (Ser81Phe)  
ParC (Ser79Tyr)


Moxifloxacin selects  
for resistance  
by target mutation  
(topoisomerases)

ParE (Ile460Val)  
ParE (Arg447Cys)




# Efflux in *S. pneumoniae*: is it important in the clinics ?

Suspected efflux based on phenotypic analysis (CIP MIC +/- reserpine)



# Efflux in *P. aeruginosa*: is it important in the clinics ?

Prevalence of MexA and MexX overexpressers in 62 phylogenetically-related pairs of *P. aeruginosa* isolated from ICU patients (VAP)




# Efflux selection in *P. aeruginosa* during treatment

Antipseudomonal antibiotics received by the patients during treatment

Antibiotic	no. patients	
Piperacillin-tazobactam (TZP)	26	69% combinations
Amikacin (AMK)	22	
Meropenem (MEM)	20	
Cefepime (CEF)	19	
Ciprofloxacin (CIP)	6	

global influence  
of treatment



# And in veterinary practice ?




# Efflux and resistance

Relative contribution of target gene mutation and efflux to  
fluoroquinolone and erythromycin resistance, in French  
poultry and pig isolates of *Campylobacter coli*

Sophie Payot<sup>a,\*</sup>, Laetitia Avraine<sup>b</sup>, Catherine Magras<sup>c</sup>, Karine Praud<sup>a</sup>,  
Axel Cloeckaert<sup>a</sup>, Elisabeth Chaslus-Dancla<sup>a</sup>

International Journal of Antimicrobial Agents 23 (2004) 468–472



Efflux involved  
in intrinsic resistance  
and low level resistance


Number	Source	MIC (mg/l)			
		Erythromycin		Enrofloxacin	
		−EPI <sup>a</sup>	+EPI <sup>b</sup>	−EPI	+EPI
C308	Poultry	0.5	0.03	0.03	≤0.03
C161		0.5	0.06	0.03	≤0.03
A7542		0.5	0.125	0.06	≤0.03
A1541		2	0.125	0.06	≤0.03
C1318	Poultry	8	0.25	4	2
C268, C606	Poultry	8	0.5	8	4
C340	Poultry	8	0.25	8	8
C342	Poultry	8	0.125	8	4
C782	Poultry	8	0.25	8	1
C1568	Poultry	8	0.125	8	2
A11321, O1511	Pig	8	0.25	8	2
O2121	Pig	8	0.5	8	4
O3911	Pig	8	0.5	16	4
A101E5, A10221, A11521	Pig	16	0.5	8	1
A10111	Pig	16	0.5	8	2
A10112, A10122, A10322, A10323, A10211	Pig	16	0.5	16	1
A10141, A10212, A10311	Pig	16	0.5	16	2
C850	Poultry	16	0.5	16	2
C1665, C1667	Poultry	16	0.5	32	8
C288	Poultry	256	128	4	2
C1332, C774	Poultry	512	128	4	1
C1578	Poultry	512	128	8	2
C1362	Poultry	>512	128	4	0.5
C1201, C776	Poultry	>512	128	4	1
C1208, C1564	Poultry	>512	256	4	2
C1256	Poultry	>512	128	4	2
C455	Poultry	>512	256	8	1
O1611	Pig	>256	256	16	8

# Risks of cross-contamination!

## Dissemination of IncFII plasmids carrying *rmtB* and *qepA* in *Escherichia coli* from pigs, farm workers and the environment

Y. Deng<sup>1</sup>, Z. Zeng<sup>1</sup>, S. Chen<sup>2</sup>, L. He<sup>1</sup>, Y. Liu<sup>1</sup>, C. Wu<sup>1,3</sup>, Z. Chen<sup>1</sup>, Q. Yao<sup>1</sup>, J. Hou<sup>1</sup>, T. Yang<sup>1</sup> and J.-H. Liu<sup>1</sup>

Clin Microbiol Infect 2011; 17: 1740–1745





Strain	Origin	PLG type	PFGE	MLST	MIC (mg/L)							Other resistance profiles	Plasmid incompatibility group	Plasmid RFLP	QRDR mutation <sup>a</sup>		Other PMQR gene(s)
					AMP	GEN	AMI	NAL	NOR	CIP	NaN <sub>3</sub>				gyrA	parC	
6-4	Weaner 2	A	UT	ST160	>256	>512	>1024	>128	>32	>64	I28	TET, STR, CHL, SXT			L83, N87	I80, A84	oqxAB
6-4-T 23-2	Boar	A	UT	ST461	>256	>512	>1024	4	>32	0.125	I024	FII	Ic		L83, N87	I80	oqxAB
18-1-T 13-5	Sow 2	A	UT	ST160	>256	>512	>1024	8	0.5	0.06	>512	TET, STR, CHL, SXT	FII	Ib	L83, N87	I80, A84	oqxAB
13-5-T 39-4	Pond water	A	UT	ST160	>256	512	>1024	8	0.25	0.03	>512	TET, STR, CHL, SXT	FII	Ib	L83, N87	I80, A84	oqxAB
3-4-T 38-4	Worker 2	A	UT	ST160	>256	512	>1024	8	I	0.125	>512	TET, STR, CHL, SXT	FII	Ib	L83, N87	I80, A84	oqxAB

# Antibiotics as inhibitors of efflux


## Killing Them with Kindness? In-Hive Medications May Inhibit Xenobiotic Efflux Transporters and Endanger Honey Bees


David J. Hawthorne\*, Galen P. Dively

Citation: Hawthorne DJ, Dively GP (2011) Killing Them with Kindness? In-Hive Medications May Inhibit Xenobiotic Efflux Transporters and Endanger Honey Bees. PLoS ONE 6(11): e26796. doi:10.1371/journal.pone.0026796





## Tetracyclines as inhibitors of efflux





# Efflux and bacteria in our team ...



# Les aventures d'un Tourangeau à Bruxelles ...

Appliqué à suivre les travaux pratiques des étudiants ...



... et à tester la gastronomie locale !